Methods of affecting hypothalamic-related conditions

• US 20050065574A1
• Filed: 07/28/2004
• Published: 03/24/2005
• Est. Priority Date: 02/01/2002
• Status: Abandoned Application

• Current Assignee: Cleveland Clinic Foundation
• Original Assignee: Cleveland Clinic Foundation
• Inventors: Rezai, Ali
• Application Number:
  US10/900,301
• Publication Number:
  US 20050065574A1
• Time in Patent Office: Days
• US Class Current: 607/45
• CPC Class Codes: A61N 1/18 Applying electric currents by contact electrodes
• CPC Class Codes: A61N 1/205 for promoting a biological process
• CPC Class Codes: A61N 1/36071 Pain

Abstract

The present invention relates to a method of affecting a hypothalamic-related condition by electrically and/or chemically stimulating the hypothalamus. Also provided are methods of stimulating a hypothalamic-related target site by responding to a sensor signal relating to a physiological activity of the body associated with the hypothalamic-related condition desired to be affected. The present invention also describes a method of directly or indirectly modulating hormones synthesized or released by the hypothalamus to affect hypothalamic-related conditions involving hormonal function, dysfunction or imbalance.

Claims

1. A method of affecting a hypothalamic-related condition comprising:

implanting a stimulator in a target site of a hypothalamic-associated circuitry; and

providing a stimulation signal to the stimulator to stimulate the target site to affect the hypothalamic-related condition, wherein the hypothalamic-related condition is not an eating disorder.

2. The method of claim 1, wherein the target site is selected from the group consisting of the hypothalamus, stria terminalis, amygdala, hippocampus, amygdalofugal fibers, lateral parabrachial nucleus, nucleus ambiguus, locus coeruleus, tuberoinfundibular tract, medial parabrachial nucleus, ventral tegmental region, medial forebrain bundle, median eminence, vagal motor nucleus, nucleus solitarius, ventral noradrenergic bundle, dorsal noradrenergic bundle, fomix, septal nuclei of fomix, nucleus of diagonal band, mammillothalamic tract, dorsal longitudinal fasciculus, ventrolateral medulla, pituitary gland, midbrain raphe nuclei, periaqueductal gray, dorsal tegmental nuclei and pineal gland.

3. The method of claim 1, wherein the stimulator is an electrode.

4. The method of claim 1, wherein the stimulator is a catheter.

5. The method of claim 1, wherein the hypothalamic-related condition is selected from the group consisting of infertility, ovulation, irregular or painful menses, lack of lactation, hyperlactation, hypogonadism, low sperm count and precocious puberty.

6. The method of claim 1, wherein the hypothalamic-related condition is selected from the group consisting of psychogenic polydipsia, diabetes insipidus, and SIADH.

7. The method of claim 1, wherein the hypothalamic-related condition is selected from the group consisting of heart failure, arrhythmia, angina, hypertension, orthostatic hypotension, pulmonary edema, and asthma.

8. The method of claim 1, wherein the hypothalamic-related condition is gastroparesis or autonomic instability.

9. The method of claim 1, wherein the hypothalamic-related condition is acromegaly or dwarfism.

10. The method of claim 1, wherein the hypothalamic-related condition is selected from the group consisting of Raynaud'"'"'s Syndrome, hyperhidrosis, hypothermia, hyperthermia and facial blushing.

11. The method of claim 1, wherein the hypothalamic-related condition is selected from the group consisting of hypothyroidism, hyperthyroidism, and prolactinoma.

12. The method of claim 1, wherein the hypothalamic-related condition is selected from the group consisting of insomnia, narcolepsy, lethargy, and circadian rhythms.

13. The method of claim 1, wherein the hypothalamic-related condition is sexual disorders or rage disorders.

14. A method of affecting a hypothalamic-related comprising:

implanting a stimulator in a target site of a hypothalamus; and

providing a stimulation signal to the stimulator to stimulate the target site to affect the hypothalamic-related condition, wherein the hypothalamic-related condition is not an eating disorder.

15. The method of claim 14, wherein the stimulator is an electrode.

16. The method of claim 14, wherein the stimulator is a catheter.

17. The method of claim 14, wherein the hypothalamic-related condition is selected from the group consisting of infertility, ovulation, irregular or painful menses, lack of lactation, hyperlactation, hypogonadism, low sperm count, impotence, baldness, and precocious puberty.

18. The method of claim 14, wherein the hypothalamic-related condition is selected from the group consisting of psychogenic polydipsia, diabetes insipidus, and SIADH.

19. The method of claim 14, wherein the hypothalamic-related condition is selected from the group consisting of heart failure, angina, hypertension, or orthostatic hypotension, pulmonary edema and asthma.

20. The method of claim 14, wherein the hypothalamic-related condition is gastroparesis or autonomic instability.

21. The method of claim 14, wherein the hypothalamic-related condition is acromegaly or dwarfism.

22. The method of claim 14, wherein the hypothalamic-related condition is selected from the group consisting of Raynaud'"'"'s Syndrome, hyperhidrosis, hypothermia, hyperthermia, and facial blushing.

23. The method of claim 14, wherein the hypothalamic-related condition is sexual disorders or rage disorders.

24. The method of claim 14, wherein the hypothalamic-related condition is selected from the group consisting of insomnia, narcolepsy, lethargy, and circadian rhythms.

25. The method of claim 14, wherein the hypothalamic-related condition is selected from the group consisting of hypothyroidism, hyperthyroidism, or pro lactinoma.

26. A method of affecting a hypothalamic-related condition comprising:

implanting a stimulator in a target site of a division of a hypothalamus; and

providing a stimulation signal to the stimulator to stimulate the target site to affect the hypothalamic-related condition, wherein the hypothalamic-related condition is not an eating disorder.

27. The method of claim 26, wherein the division is a periventricular division of the hypothalamus, the periventricular division comprising the arcuate nucleus, paraventricular nucleus, periventricular nucleus, tuberoinfindibular tract, stria terminalis, dorsal longitudinal fasciculus, fomix, medial forebrain bundle, and optic chiasm.

28. The method of claim 27, wherein the hypothalamic-related condition is selected from the group consisting of chronic pain, gastroparesis, orthostatic hypotension, arrythymia, heart failure, hypertension, pulmonary edema, prolactinoma, SIADH, diabetes insipidus, lethargy, coma, acromegaly, dwarfism, infertility, ovulation, irregular or painful menses, hypogonadism, low sperm count, precocious puberty;

lack of lactation, hyper-lactation, hypothyroidism, hyperthyroidism, addictions, psychogenic polydipsia, Raynaud'"'"'s Syndrome, hyperthermia, fear, anxiety, sexual disorders, rage disorders, hypothermia, angina, depression, insomnia, hyperhidrosis, narcolepsy, circadian rhythms, autonomic instability, asthma, or facial blushing.

29. The method of claim 26, wherein the division is the medial division of the hypothalamus, the medial division comprising the anterior nucleus, supraoptic nucleus, preoptic nucleus, mammillary body, ventromedial nucleus, dorsomedial nucleus, posterior nucleus, substantia innominata, basal nucleus of meynert, stria terminalis, tuberoinfundibular tract, parasympathetic efferents from the hypothalamus, dorsal longitudinal fasciculus, medial forebrain bundle, fomix, mammillothalamic tract, mammillary peduncle, and pallidohypothalamic tract.

30. The method of claim 29, wherein the hypothalamic-related condition is selected from the group consisting of addiction, sexual disorders, hyperhidrosis, hyperthermia, psychogenic polydipsia, Raynaud'"'"'s Syndrome, infertility, ovulation, irregular or painful menses, hypogonadism, low sperm count;

precocious puberty, lack of lactation, hyper-lactation,SIADH, diabetes insipidus, gastroparesis, hypertension, angina, arrhythmia, rage disorder, depression, epilepsy, movement disorders, taste disorders, heart failure, hypothermial, insomnia, narcolepsy, hypothyroidism, hyperthyroidism, lethargy, acromegaly, dwarfism, orthostatic hypotension, chronic pain, and asthma.

31. The method of claim 26, wherein the division is the lateral division of the hypothalamus, the lateral division comprising the preoptic nucleus, supraoptic nucleus, lateral nucleus, tuberal nuclei, medial forebrain bundle, fomix, amygdalofugal fibers, parasympathetic efferents from the hypothalamus, stria terminalis, median eminence, tuberoinfundibular tract, and dorsal longitudinal fasciculus.

32. The method of claim 31, wherein the hypothalamic-related condition is selected from the group consisting of rage, depression, anxiety, epilepsy, addiction, chronic pain, infertility, ovulation, irregular or painful menses, hypogonadism, low sperm count, precocious puberty, gastroparesis, hypertension, angina, arrythymia, Raynaud'"'"'s Syndrome, lack of lactation, hyper-lactation, SIADH, diabetes insipidus, hypothermia, Orthostatic hypotension, acromegaly, dwarfism, heart failure, rage disorder, depression, insomnia, lethargy, coma, hyperhidrosis, sexual disorders, psychogenic polydipsia, hypothyroidism, hyperthyroidism, pulmonary edema, asthma, chronic pain, and autonomic dysfunction.

33. A method of affecting a hypothalamic-related condition comprising:

implanting a stimulator in a nucleus of the hypothalamus; and

providing a stimulation signal to the stimulator to stimulate the nucleus of the hypothalamus to affect the hypothalamic-related condition, wherein the hypothalamic-related condition is not an eating disorder.

34. The method of claim 33, wherein the nucleus of the hypothalamus is selected from the group consisting of the paraventricular nucleus, preoptic nucleus, supraoptic nucleus, anterior nucleus, suprachiasmatic nucleus, ventromedial nucleus, dorsomedial nucleus, arcuate nucleus, lateral nucleus, posterior nucleus, substantia innominata, basal nucleus of meynert, and mammillary body.

35. The method of claim 33, wherein the nucleus is an anterior nucleus and the hypothalamic-related condition is selected from the group consisting of addiction, fear, anxiety, sexual disorders, hyperhidrosis, hyperthermia, psychogenic polydipsia, Raynaud'"'"'s Syndrome, infertility, ovulation, irregular menses or painful menses, hypogonadism, low sperm count, impotence, baldness and precocious puberty.

36. The method of claim 33, wherein the nucleus is an arcuate nucleus and the hypothalamic-related condition is selected from the group consisting of lack of lactation, hyper-lactation, chronic pain, infertility, ovulation, irregular menses, painful menses, hypogonadism, low sperm count, impotence, baldness and precocious puberty.

37. The method of claim 33, wherein the nucleus is a parventricular nucleus and the hypothalamic-related condition is selected from the group consisting of chronic pain, gastroparesis, Orthostatic hypertension, arrythymia, heart failure;

hypothyroidism, hyperthyroidism, hypertension, pulmonary edema;

no lactation, hyper-lactation, prolactinoma, SIADH, diabetes insipidus, lethargy, coma, acromegaly, and dwarfism.

38. The method of claim 33, wherein the nucleus in a supraoptic nucleus and the hypothalamic-related condition is selected from the group consisting of addictions, no lactation, hyper-lactation, SLADH, diabetes insipidus, gastroparesis, hypertension, angina, arrhythmia, impotence, and Raynaud'"'"'s Syndrome.

39. The method of claim 33, wherein the nucleus is a suprachiasmatic nucleus and the hypothalamic-related condition is selected from the group consisting of circadian rhythms, insomnia, and narcolepsy.

40. The method of claim 33, wherein the nucleus is a preoptic nucleus and the hypothalamic-related condition is selected from the group consisting of rage, depression, anxiety, epilepsy, addiction, chronic pain, infertility, ovulation, irregular or painful menses, hypogonadism, low sperm count, precocious puberty;

gastroparesis, hypertension, angina, arrythymia, impotence, baldness, and Raynaud'"'"'s Syndrome

41. The method of claim 33, wherein the nucleus is a lateral nucleus and the hypothalamic-related condition is selected from the group consisting of rage disorder;

Epilepsy, anxiety, addictions, obsessive-compulsive disorder, heart failure, hypothermia, insomnia, narcolepsy, gastroparesis, hypertension, angina, arrhythmia, Raynaud'"'"'s Syndrome, hyperhidrosis, hyperthermia, psychogenic polydipsia.

42. The method of claim 33, wherein the nucleus is a mammillary body and the hypothalamic-related condition is selected from the group consisting of epilepsy, chronic pain, gastroparesis, hypertension, and angina.

43. The method of claim 33, wherein the nucleus is a ventromedial nucleus and the hypothalamic-related condition is selected from the group consisting of chronic pain, addictions, rage disorder, movement disorders, psychiatric disorders, infertility, ovulation, irregular or painful menses, hypogonadism, low sperm count, impotence, baldness and precocious puberty.

44. The method of claim 33, wherein the nucleus is a dorsomedial nucleus and the hypothalamic-related condition is selected from the group consisting of epilepsy, chronic pain, depression, rage, hypothyroidism, and hyperthyroidism.

45. The method of claim 33, wherein the nucleus is a posterior nucleus and the hypothalamic-related condition is selected from the group consisting of chronic pain, taste disorder, rage disorder, hypertension, anxiety, heart failure, hypothermia, insomia, narcolepsy, precocious puberty, and hypogonadism.

46. The method of claim 33, wherein the nucleus is a substantia innominata and the hypothalamic-related condition is taste disorder.

47. The method of claim 33, wherein the nucleus is a basal nucleus of meynert and the hypothalamic-related condition is Alzheimer'"'"'s disease or dementia.

48. A method of affecting a hypothalamic-related condition comprising:

implanting a stimulator in a target site of a hypothalamus; and

providing a stimulation signal to the stimulator to stimulate the target site to modulate the synthesis or release of a hypothalamic or pituitary product.

49. The method of claim 48, wherein the hypothalamic or pituitary product is a hormone.

50. A method of affecting a hypothalamic-related condition comprising:

implanting a stimulator in a target site of a pituitary gland; and

providing a stimulation signal to the stimulator to stimulate the target site to modulate the synthesis or release of a hypothalamic or pituitary product.

51. The method of claim 50, wherein the hypothalamic or pituitary product is a hormone.

52. A method of affecting a hypothalamic-related condition comprising:

implanting a stimulator in communication with a hypothalamic-related target site;

detecting a physiological activity of the body associated with the hypothalamic-related condition to generate a sensor signal;

providing a stimulation signal to the stimulator in response to the sensor signal; and

stimulating the target site to affect the hypothalamic-related condition.